Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development

J Biomed Biotechnol. 2011;2011:907461. doi: 10.1155/2011/907461. Epub 2011 Jun 1.

Abstract

The concept of physiologically based pharmacokinetic (PBPK) modeling was introduced years ago, but it has not been practiced significantly. However, interest in and implementation of this modeling technique have grown, as evidenced by the increased number of publications in this field. This paper demonstrates briefly the methodology, applications, and limitations of PBPK modeling with special attention given to discuss the use of PBPK models in pediatric drug development and some examples described in detail. Although PBPK models do have some limitations, the potential benefit from PBPK modeling technique is huge. PBPK models can be applied to investigate drug pharmacokinetics under different physiological and pathological conditions or in different age groups, to support decision-making during drug discovery, to provide, perhaps most important, data that can save time and resources, especially in early drug development phases and in pediatric clinical trials, and potentially to help clinical trials become more "confirmatory" rather than "exploratory".

Publication types

  • Review

MeSH terms

  • Child
  • Clinical Trials as Topic
  • Drug Design*
  • Humans
  • Models, Biological*
  • Pharmacokinetics*
  • Risk Assessment